Tenax Therapeutics, Inc. (TENX)
| Market Cap | 861.98M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -52.60M |
| Shares Out | 58.88M |
| EPS (ttm) | -1.34 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 925,435 |
| Open | 15.05 |
| Previous Close | 15.11 |
| Day's Range | 13.52 - 15.10 |
| 52-Week Range | 5.34 - 18.38 |
| Beta | 1.19 |
| Analysts | Strong Buy |
| Price Target | 29.67 (+102.66%) |
| Earnings Date | May 13, 2026 |
About TENX
Tenax Therapeutics, Inc., a development-stage pharmaceutical company, develops novel cardiopulmonary therapies in the United States. It develops TNX-101, TNX-102, and TNX-103 (levosimendan) that have completed phase II clinical trials for the treatment of patients with pulmonary hypertension in heart failure with preserved ejection fraction and associated pulmonary hypertension; and TNX-201 (imatinib), a tyrosine kinase inhibitor for the treatment of chronic myeloid leukemia. The company was formerly known as Oxygen Biotherapeutics, Inc. and ch... [Read more]
Financial Performance
Financial StatementsAnalyst Forecast
According to 3 analysts, the average rating for TENX stock is "Strong Buy." The 12-month stock price target is $29.67, which is an increase of 102.66% from the latest price.
News
Tenax Therapeutics Appoints Thomas R. Staab, II as Chief Financial Officer
Mr. Staab has over 25 years of financial and executive experience across the healthcare industry CHAPEL HILL, N.C., April 22, 2026 (GLOBE NEWSWIRE) -- Tenax Therapeutics, Inc. (Nasdaq: TENX) (“Tenax” ...
Tenax Therapeutics Transcript: Leerink Global Healthcare Conference 2026
LEVEL trial completed enrollment ahead of schedule, with results expected in Q3 and strong patient retention. The global LEVEL-2 trial will expand reach and duration, while regulatory strategy focuses on robust safety and efficacy data. Cash runway and infrastructure support ongoing growth.
Tenax Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Update
Achieved randomization target of 230 patients in LEVEL study, topline data expected in third quarter of 2026 Initiated global Phase 3 LEVEL-2 clinical trial and opened long-term OLE study for patients...
Tenax Therapeutics to Participate in the 2026 Leerink Partners Global Healthcare Conference
CHAPEL HILL, N.C., March 03, 2026 (GLOBE NEWSWIRE) -- Tenax Therapeutics, Inc. (Nasdaq: TENX) (“Tenax” or “Tenax Therapeutics” or the “Company”), a Phase 3, development-stage pharmaceutical company us...
Tenax Therapeutics Transcript: Guggenheim Securities Emerging Outlook: Biotech Summit 2026
Phase III trials for levosimendan in PH-HFpEF are progressing globally, with robust patient enrollment and strong statistical power. The drug shows significant clinical benefits, high patient compliance, and targets a large, underserved market with a differentiated oral therapy profile.
Tenax Therapeutics to Participate in the Guggenheim Emerging Outlook Biotech Summit 2026
CHAPEL HILL, N.C., Feb. 04, 2026 (GLOBE NEWSWIRE) -- Tenax Therapeutics, Inc. (Nasdaq: TENX) (“Tenax” or “Tenax Therapeutics” or the “Company”), a Phase 3, development-stage pharmaceutical company usi...
Tenax Therapeutics Announces Result of Prespecifed Blinded Sample Size Assessment
Planned Review of Standard Deviation Demonstrates No Need to Increase Size of Ongoing LEVEL Study LEVEL On Track to Complete Enrollment in First Half of 2026; Topline Data Expected in Second Half of 2...
Tenax Therapeutics Transcript: Piper Sandler 37th Annual Healthcare Conference
LEVEL phase III trial enrollment increased to 230, with results expected in the second half of next year. Both LEVEL 1 and LEVEL 2 use rigorous design, identical patient criteria, and a 3 mg oral dose, with LEVEL 2 expanding globally and extending to 26 weeks. Open-label extensions ensure patient access.
Tenax Therapeutics Transcript: Evercore ISI 8th Annual HealthCONx Conference
Phase III enrollment for PH-HFpEF is underway, with a second global trial starting soon and data expected in the second half of next year. The drug targets wedge pressure and has shown efficacy in prior studies, with a large addressable market and funding secured through 2027.
Tenax Therapeutics to Participate in Upcoming Investor Conferences
CHAPEL HILL, N.C., Nov. 25, 2025 (GLOBE NEWSWIRE) -- Tenax Therapeutics, Inc. (Nasdaq: TENX) (“Tenax Therapeutics” or the “Company”), a Phase 3, development-stage pharmaceutical company using clinical...
Tenax Therapeutics Transcript: KOL Event
Experts highlighted TNX-103's unique mechanism and strong clinical data in PH-HFpEF, emphasizing its differentiation from failed vasodilator and Relaxin trials. The oral formulation showed improved patient outcomes, robust patent protection, and potential as an add-on therapy.
Tenax Therapeutics Reports Third Quarter 2025 Financial Results and Provides Corporate Update
Phase 3 LEVEL Study Ongoing, Enrollment Completion (230 Patients) Expected in First Half of 2026, with Topline Data Expected in Second Half of 2026
Tenax Therapeutics Transcript: Guggenheim Securities 2nd Annual Healthcare Innovation Conference
Levosimendan is advancing in phase 3 trials for PH-HFpEF, targeting a large unmet market with no approved therapies. The oral formulation shows sustained patient benefit, strong adherence, and promising clinical endpoints, with global expansion and robust IP protection.
Tenax Therapeutics to Host Virtual KOL Call to Discuss TNX-103 (Oral Levosimendan) for the Treatment of PH-HFpEF
CHAPEL HILL, N.C., Nov. 06, 2025 (GLOBE NEWSWIRE) -- Tenax Therapeutics, Inc. (Nasdaq: TENX) (“Tenax Therapeutics” or the “Company”), a Phase 3, development-stage pharmaceutical company using clinical...
Tenax Therapeutics to Participate in the Guggenheim 2nd Annual Healthcare Innovation Conference
CHAPEL HILL, N.C., Nov. 03, 2025 (GLOBE NEWSWIRE) -- Tenax Therapeutics, Inc. (Nasdaq: TENX) (“Tenax Therapeutics” or the “Company”), a Phase 3, development-stage pharmaceutical company using clinical...
Tenax Therapeutics Announces European Patent Office Intention to Grant Patent Covering Use of Levosimendan in PH-HFpEF
Provides Patent Protection in Europe Through at Least December 2040 Further IP Protection for TNX-103 (Oral Levosimendan) and Other Drug Formulations, and its Active Metabolites, in PH-HFpEF Also Prov...
Tenax Therapeutics Transcript: Cantor Global Healthcare Conference 2025
A late-stage oral therapy for group two pulmonary hypertension is advancing through two global Phase III trials, targeting a $10B market with no approved treatments. Strong legacy data, successful transition from IV to oral, and robust trial design underpin confidence, with key milestones expected through 2027.
Tenax Therapeutics to Participate in the Cantor Global Healthcare Conference 2025
CHAPEL HILL, N.C., Aug. 28, 2025 (GLOBE NEWSWIRE) -- Tenax Therapeutics, Inc. (Nasdaq: TENX) (“Tenax Therapeutics” or the “Company”), a Phase 3, development-stage pharmaceutical company using clinical...
Tenax Therapeutics Reports Second Quarter 2025 Financial Results and Provides Corporate Update
Phase 3 LEVEL Study Ongoing, Enrollment Completion (230 Patients) Expected in First Half of 2026, with Topline Data Expected in Second Half of 2026
Tenax Therapeutics Reports First Quarter 2025 Financial Results and Provides Corporate Update
Phase 3 LEVEL Enrollment Completion for TNX-103 in PH-HFpEF Targeted Around Year-End 2025, with Topline Data Expected Middle of 2026
Tenax Therapeutics Transcript: 24th Annual Needham Virtual Healthcare Conference
A novel oral therapy for PH-HFpEF is in Phase III, with expanded trials and strong FDA alignment. Phase II data showed significant improvements in exercise tolerance, and the addressable market is estimated at $10 billion. Investor and payer interest is high.
Tenax Therapeutics to Participate in the 24th Annual Needham Virtual Healthcare Conference
CHAPEL HILL, N.C., March 31, 2025 (GLOBE NEWSWIRE) -- Tenax Therapeutics, Inc. (Nasdaq: TENX) (“Tenax Therapeutics” or the “Company”), a Phase 3, development-stage pharmaceutical company using clinica...
Tenax Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Corporate Update
Successfully Completed Private Placements with Aggregate Gross Proceeds of Approximately $125 Million to Support Advancement of Two Registrational Studies for TNX-103 in PH-HFpEF and Fund Operations t...
Tenax Therapeutics Transcript: Leerink’s Global Healthcare Conference 2025
Leadership highlighted robust clinical and regulatory progress, including expanded phase 3 trials for oral levosimendan in PH-HFpEF, strong patient adherence, and a large market opportunity. Patent protection extends to 2042, and funding is secured through 2027.
Tenax Therapeutics Announces $25 Million Private Placement
CHAPEL HILL, N.C., March 05, 2025 (GLOBE NEWSWIRE) -- Tenax Therapeutics, Inc. (Nasdaq: TENX) (the “Company” or “Tenax Therapeutics”), a Phase 3, development-stage pharmaceutical company using clinica...